No Significant Association Between Allergic Rhinitis and Rheumatoid Arthritis
Based on 12 studies, the pooled analysis showed no association between allergic rhinitis and risk of rheumatoid arthritis.
Allergies
High Rates of Inappropriate Antibiotic Prescribing for Acute Sinusitis in Primary Care
A study revealed that primary care clinicians do not closely follow clinical practice guidelines with regard to antibiotic prescribing for acute sinusitis and frequently overprescribe antibiotics.
Fossil Fuel Decrease in COVID-19 Quarantine May Positively Affect Allergic Diseases
Global quarantine as a result of the COVID-19 pandemic has decreased fossil fuel use which may affect allergic and respiratory diseases.
Accuracy of Skin Tests and Immunoglobulin E Quantification in Penicillin Allergy
Skin tests and specific immunoglobulin E quantification had high specificity and low sensitivity in identifying patients who may develop a hypersensitivity reaction from penicillin exposure.
Subcutaneous C1-Inhibitor Well-Tolerated, Effective in Hereditary Angioedema
Older patients with hereditary angioedema who were treated with a subcutaneous injection of C1-INH had fewer attacks than pre-study levels.
Avoiding COVID-19 in Children With Asthma and Allergies
Social distancing of families with children who have asthma is the best method for preventing coronavirus diseases 2019.
FDA: Certain Epinephrine Autoinjector Devices May Have Missing Safety Component
Certain lots of Amneal’s Epinephrine Injection, Autoinjector 0.3mg may not contain the yellow “stop collar” that is necessary for proper dosing of the anaphylaxis treatment, according to the FDA.
Mepolizumab Gets Priority Review for Hypereosinophilic Syndrome
The FDA previously granted Fast Track and Orphan Drug designations to mepolizumab for the treatment of HES.
Clinical, Anatomic Improvements With Dupilumab in Eosinophilic Esophagitis Study
Dupilumab was associated with clinical and anatomic improvements in patients with eosinophilic esophagitis, according to results from a pivotal phase 3 study.
Dupilumab Approval Expanded to Pediatric Patients With Atopic Dermatitis
The FDA has expanded the approval of dupilumab to include patients aged 6 to 11 years with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
-
Loading...
-
Loading...
Next post in Asthma
